Achieving durable viral suppression in children and adolescents requires earlier diagnosis, optimized child-friendly regimens, routine resistance testing, and integrated management of comorbidities. Key priorities include pediatric evaluation of long-acting and novel agents, development of improved immunologic and virologic markers, and scalable approaches to strengthen engagement in care and reduce global inequities.
Borjesson et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: